Novartis bags Adakveo FDA approval to reduce VOCs in sickle cell disease
Adakveo FDA approval : Swiss drugmaker Novartis has bagged approval for Adakveo (crizanlizumab-tmca) from the US Food and…
Roche to acquire US biotech company Promedior for $1.4bn
Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a…
Terason, DiA bring AI-based cardiac solutions for ultrasound devices
Terason, a US ultrasound imaging company, has partnered with DiA Imaging Analysis, an artificial intelligence-based solutions provider for…
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquisition of Calporta : Merck has acquired Calporta Therapeutics from COI Pharmaceuticals in a deal worth up…
Cancer immunotherapy company EpicentRx raises $35m in Series D round
EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D…
ProteKt secures funding for PKR kinase inhibitor-based therapies
Israeli biotech company ProteKt Therapeutics, which is focused on developing new PKR kinase inhibitor-based therapies for Alzheimer’s Disease…
Novartis’ Sandoz to acquire Aspen’s Japanese pharma business
Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated…
Novartis’ Sandoz to acquire Aspen’s Japanese pharma business
Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen Pharmacare in a deal valued up to €400 million, as per the latest pharma acquisition news. The acquisition includes shares in Aspen Japan and associated assets held by the South […]
F2G gets olorofim breakthrough therapy status from FDA for mold infections
F2G has secured breakthrough therapy designation to olorofim (formerly F901318) from the US Food and Drug Administration (FDA)Â …
F2G gets olorofim breakthrough therapy status from FDA for mold infection
F2G has secured breakthrough therapy designation to olorofim (formerly F901318) from the US Food and Drug Administration (FDA) for the treatment of invasive mold infections. The breakthrough therapy designation is for the use of olorofim in patients having limited or no treatment options, and also those who are intolerant to currently available therapy for their […]